chartexchange

Eikon Therapeutics Announces Clearance to Proceed with First-in-Human Phase 1/2 Study for Novel Androgen Receptor Antagonist EIK1006 in Advanced Metastatic Prostate Cancer 

GlobeNewswire Inc. | Nov 17, 2026 6:00 AM EST

MILLBRAE, Calif., Nov. 17, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced U.S. Food and Drug Administration clearance to proceed for the Investigational New Drug (IND) application to evaluate EIK1006 for the treatment of advanced metastatic prostate cancer. 

Read original article